FDA flags potential VEGF-related safety concern in Summit rejection letter
The FDA flagged a safety issue in its review of Summit Therapeutics’ and Akeso's now-rejected cancer drug ivonescimab, raising questions about the viability of the whole class of new bispecifics, though the ...
comments(0)
5-min edit window · permanent after that